Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus Endocrine Therapy vs Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast Cancer
NCT04055493Phase 3Active, not recruiting
- Sponsor
- Women's Cancer Study Group
- Start
- Jul 2019
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Ribociclib plus ET with Standard-of-care chemotherapy (2 arms). Primary endpoints: Invasive Disease-Free Survival at 5 years and Distant Disease-Free Survival at 5 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04055493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055493.